SLFN11 and gastric carcinoma: In vitro observations have implicated SLFN11 as a potential marker of cancer cell chemosensitivity to agents as diverse as PARPi [69,101,102,103,104,105,106], platinum-based drugs [21,65,69,94,107], topoisomerase inhibitors [18,108,109,110,111,112], and antibody-drug conjugates [112] in a variety of tumor types including breast [67,94,101], lung [21,67,101,103,104,107], ovarian [21,67], prostate [69,101], colon [101,108], Ewing sarcoma [101,109], gastric carcinoma [65], and leukemias [108,111].